QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hazelwood, L. A. Articles by Sanders-Bush, E. Search for Related Content PubMed PubMed Citation Articles by Hazelwood, L. A. Articles by Sanders-Bush, E.

His452Tyr Polymorphism in the Human 5-HT_2A Receptor Destabilizes the Signaling Conformation

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee

Naturally occurring variation within the human 5-HT_2A receptor results in an amino acid substitution in the carboxyl terminus of the receptor. This single nucleotide polymorphism (SNP), encoding a His452Tyr substitution, occurs at a frequency of 9% in the general population. It is noteworthy that this SNP has been linked to attention deficit hyperactivity disorder and has been associated with schizophrenic patients that do not respond to treatment with clozapine. To evaluate functional consequences of this SNP, agonist-stimulated signaling was investigated in NIH3T3 cells stably expressing either wild-type or 452Tyr variant receptors. The 452Tyr variant of the 5-HT_2A receptor had reduced ability to activate phospholipases C and D, suggesting that signaling through both G_q and G₁₃ pathways is hindered. This conclusion was supported by assays of G protein coupling, which documented a loss of agonist-induced high affinity binding and a decreased turnover of guanosine 5'-O-(3-[³⁵S]thio)triphosphate after agonist stimulation. Kinetic analysis of time-course data revealed an altered desensitization phenotype, resulting in a blunted signal downstream of receptor activation. This diminished signaling implies that the His452Tyr variant receptor alters physiological responses, possibly contributing to psychiatric disease.

Address correspondence to: Elaine Sanders-Bush, 8140 MRB III/Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-8548. E-mail: elaine.bush{at}vanderbilt.edu